Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLINASDAQ:CLNNNASDAQ:GBIONASDAQ:RLYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$1.11+2.2%$1.54$1.00▼$10.05$7.27M0.658,162 shs73,249 shsCLNNClene$3.00+4.9%$4.06$2.57▼$9.20$24.59M0.4679,379 shs80,510 shsGBIOGeneration Bio$0.37+16.4%$0.54$0.32▼$4.34$24.96M2.78270,833 shs944,463 shsRLYBRallybio$0.25$0.67$0.22▼$3.46$10.40M-1.35482,377 shs440,096 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+2.25%-7.89%-31.63%-46.67%-87.24%CLNNClene+4.90%0.00%-31.82%-43.18%-61.73%GBIOGeneration Bio+14.97%+0.62%-24.75%-59.07%-90.64%RLYBRallybio0.00%-56.90%-62.50%-74.90%-84.85%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics3.3166 of 5 stars3.53.00.04.70.00.00.6CLNNClene2.9145 of 5 stars3.65.00.00.01.12.50.6GBIOGeneration Bio3.6374 of 5 stars3.55.00.00.00.65.01.3RLYBRallybio2.2901 of 5 stars3.32.00.00.02.31.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 3.00Buy$30.002,591.79% UpsideCLNNClene 3.20Buy$55.251,741.67% UpsideGBIOGeneration Bio 3.00Buy$7.331,868.68% UpsideRLYBRallybio 2.60Moderate Buy$9.753,800.00% UpsideCurrent Analyst Ratings BreakdownLatest BCLI, RLYB, GBIO, and CLNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025RLYBRallybioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral4/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/8/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/24/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/24/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/17/2025GBIOGeneration BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/17/2025RLYBRallybioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/14/2025GBIOGeneration BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/14/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/12/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/12/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.20) per shareN/ACLNNClene$342K75.40N/AN/A$2.09 per share1.44GBIOGeneration Bio$19.89M1.25N/AN/A$3.07 per share0.12RLYBRallybio$636K16.36N/AN/A$2.81 per share0.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$3.66N/AN/AN/AN/AN/A-528.56%5/13/2025 (Estimated)CLNNClene-$49.50M-$5.75N/AN/AN/A-8,556.77%-1,106.30%-85.11%5/6/2025 (Estimated)GBIOGeneration Bio-$126.61M-$1.98N/AN/AN/A-782.86%-104.85%-49.54%5/12/2025 (Estimated)RLYBRallybio-$74.56M-$1.35N/AN/AN/AN/A-77.39%-69.33%5/8/2025 (Estimated)Latest BCLI, RLYB, GBIO, and CLNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025N/ARLYBRallybio-$0.26N/AN/AN/AN/AN/A3/24/2025Q4 2024CLNNClene-$1.21-$1.67-$0.46-$1.67$0.13 million$0.09 million3/19/2025Q4 2024GBIOGeneration Bio-$0.31-$0.32-$0.01-$0.32$2.92 million$4.19 million3/13/2025Q4 2024RLYBRallybio-$0.27-$0.25+$0.02-$0.25$0.15 million$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.050.05CLNNCleneN/A0.830.82GBIOGeneration BioN/A6.346.34RLYBRallybioN/A9.559.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%CLNNClene23.28%GBIOGeneration Bio95.22%RLYBRallybio90.34%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics6.70%CLNNClene25.10%GBIOGeneration Bio21.10%RLYBRallybio7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics406.52 million5.32 millionOptionableCLNNClene1008.60 million6.24 millionOptionableGBIOGeneration Bio15067.01 million52.70 millionOptionableRLYBRallybio4041.61 million38.42 millionNot OptionableBCLI, RLYB, GBIO, and CLNN HeadlinesRecent News About These CompaniesRallybio Stock Short Interest Report | NASDAQ:RLYB | BenzingaApril 9 at 10:15 PM | benzinga.comRallybio discontinues RLYB212 programApril 9 at 5:15 PM | markets.businessinsider.comRallybio sinks as it drops RLYB212 for prevention of FNAITApril 9 at 5:15 PM | thepharmaletter.comHC Wainwright & Co. Downgrades Rallybio (RLYB)April 9 at 5:15 PM | msn.comRLYB Ends Pregnancy-Related Rare Disease Program, Stock TanksApril 9 at 12:00 PM | zacks.comCitizens JMP downgrades Rallybio on RLYB212 discontinuationApril 9 at 6:04 AM | markets.businessinsider.comJMP Securities downgrades Rallybio (RLYB) to a HoldApril 9 at 1:03 AM | theglobeandmail.comRallybio Stock Plunges After Program For Pediatric Bleeding Disorder DisappointsApril 8 at 1:01 PM | benzinga.comRallybio Discontinues Development of Treatment for Prevention of Rare Immune DisorderApril 8 at 10:00 AM | marketwatch.comRallybio to Discontinue Development of RLYB212 for Prevention of FNAITApril 8 at 10:00 AM | finance.yahoo.comRallybio reports Q4 EPS (25c), consensus (30c)March 13, 2025 | markets.businessinsider.comRallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 13, 2025 | finance.yahoo.comNew Haven-based biotech Rallybio faces delisting from NasdaqFebruary 28, 2025 | hartfordbusiness.comRallybio to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | finance.yahoo.comRallybio to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | businesswire.comRallybio stock plunges to 52-week low of $0.73 amid market challengesFebruary 13, 2025 | msn.comJMP Securities Sticks to Their Buy Rating for Rallybio (RLYB)February 11, 2025 | markets.businessinsider.comRallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical TrialFebruary 11, 2025 | finance.yahoo.comRallybio begins Phase 2 trial for FNAIT prevention therapyFebruary 11, 2025 | msn.comRallybio announces initiation of dosing in RLYB212 Phase 2 trialFebruary 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCLI, RLYB, GBIO, and CLNN Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$1.11 +0.02 (+2.25%) Closing price 04/9/2025 03:47 PM EasternExtended Trading$1.11 0.00 (-0.40%) As of 04/9/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Clene NASDAQ:CLNN$3.00 +0.14 (+4.90%) Closing price 04/9/2025 04:00 PM EasternExtended Trading$3.08 +0.08 (+2.67%) As of 04/9/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Generation Bio NASDAQ:GBIO$0.37 +0.05 (+16.41%) Closing price 04/9/2025 04:00 PM EasternExtended Trading$0.37 0.00 (-0.67%) As of 04/9/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Rallybio NASDAQ:RLYB$0.25 0.00 (0.00%) Closing price 04/9/2025 04:00 PM EasternExtended Trading$0.25 0.00 (-0.40%) As of 04/9/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Alphabet a Generational Buying Opportunity at These Levels? Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Strategy’s $5 Million Bitcoin Target: Beacon or Bagholder? Amazon Stock Bounces From Lows as Smart Money Steps In Qualcomm Breaks Down But RSI Signals It’s Severely Oversold Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
